| Literature DB >> 30505948 |
Eugenia Bifeld1, Stephan Lorenzen2, Katharina Bartsch1, Juan-José Vasquez3, T Nicolai Siegel3,4,5, Joachim Clos1.
Abstract
The 90-kDa heat shock protein (HSP90) of eukaryotes is a highly abundant and essential chaperone required for the maturation of regulatory and signal proteins. In the protozoan parasite Leishmania donovani, causative agent of the fatal visceral leishmaniasis, HSP90 activity is essential for cell proliferation and survival. Even more importantly, its inhibition causes life cycle progression from the insect stage to the pathogenic, mammalian stage. To unravel the molecular impact of HSP90 activity on the parasites' gene expression, we performed a ribosome profiling analysis of L. donovani, comparing genome-wide protein synthesis patterns in the presence and absence of the HSP90-specific inhibitor radicicol and an ectopically expressed radicicol-resistant HSP90 variant. We find that ribosome-protected RNA faithfully maps open reading frames and represents 97% of the annotated protein-coding genes of L. donovani. Protein synthesis was found to correlate poorly with RNA steady-state levels, indicating a regulated translation as primary mechanism for HSP90-dependent gene expression. The results confirm inhibitory effects of HSP90 on the synthesis of Leishmania proteins that are associated with the pathogenic, intracellular stage of the parasite. Those include heat shock proteins, redox enzymes, virulence-enhancing surface proteins, proteolytic pathways, and a complete set of histones. Conversely, HSP90 promotes fatty acid synthesis enzymes. Complementing radicicol treatment with the radicicol-resistant HSP90rr variant revealed important off-target radicicol effects that control a large number of the above-listed proteins. Leishmania lacks gene-specific transcription regulation and relies on regulated translation instead. Our ribosome footprinting analysis demonstrates a controlling function of HSP90 in stage-specific protein synthesis but also significant, HSP90-independent effects of the inhibitor radicicol. IMPORTANCE Leishmania parasites cause severe illness in humans and animals. They exist in two developmental stages, insect form and mammalian form, which differ in shape and gene expression. By mapping and quantifying RNA fragments protected by protein synthesis complexes, we determined the rates of protein synthesis for >90% of all Leishmania proteins in response to the inhibition of a key regulatory protein, the 90-kDa heat shock protein. We find that Leishmania depends on a regulation of protein synthesis for controlling its gene expression and that heat shock protein 90 inhibition can trigger the developmental program from insect form to mammalian form of the pathogen.Entities:
Keywords: HSP90; Leishmania donovani; radicicol; ribosome profiling
Year: 2018 PMID: 30505948 PMCID: PMC6247020 DOI: 10.1128/mSystems.00214-18
Source DB: PubMed Journal: mSystems ISSN: 2379-5077 Impact factor: 6.496
FIG 1Experimental setup. (A) Schematic representation of biological samples used in the analysis showing (i) HSP90 able to bind ATP (orange), (ii) HSP90 bound by RAD, and (iii) HSP90rr able to bind ATP, no binding of RAD. N, N-terminal domain; M, middle domain; C, C-terminal domain. (B) Flow chart of ribosome profiling analysis.
FIG 2Verification of ribosome footprints. (A) Read mapping analysis of RNA-Seq (gray) and RFPs (purple) on a cluster of three ribosomal protein-coding genes on chromosome 21. Blue arrows delineate annotated coding sequences with gene IDs. Read alignment densities for RNA-Seq (top panel) and RFP (bottom panel) are depicted. (B and C) The 30-nt ribosome footprints (black bars) of the representative sample HSP90rr+RAD were mapped to the annotated CDSs in relation to the initiation (B) and termination (C) sites and plotted by the first nucleotides of the P-sites. Corresponding RNA-Seq reads are shown as blue peaks. Note that peak densities occur at 3-nt intervals for RFPs, representing 3-nt increments of ribosome movement.
FIG 3Identification of uORFs and extended coding sequences. (A) Position of the HSP100 CDS on chromosome 29; ruler shows position in kilobase pairs. (B) RNA-Seq read alignment at the HSP100 gene locus. (C) RFP read alignment at the HSP100 gene locus. (D) Enlargement of the 5′ UTR of HSP100 showing RFPs aligned to an upstream AUG codon, representing a putative uORF. (E) Zoom into the translation initiation site of HSP100 represented by RFP reads aligning 12 nucleotides upstream of the AUG start codon. The blue bar represents the start of the HSP100 CDS. (F) Possible erroneous annotation of the LinJ.30.0460 (eIF4-E4) CDS, with RFP reads aligning well upstream of the annotated AUG start codon. Annotated and experimentally determined CDSs are shown as arrows.
FIG 4Correlation analysis. ΔRFP was plotted against ΔRNA for (A) WT+RAD/WT-RAD, (B) WT+RAD/HSP90rr+RAD, and (C) HSP90rr+RAD/WT-RAD. The coefficients of determination, R2, are displayed. (D) Plot of overall ΔRFP (WT+RAD/WT-RAD) against on-target ΔRFP (WT+RAD/HSP90rr+RAD) with coefficient of determination, R2. (E) Plot of overall ΔRFP (WT+RAD/WT-RAD) against off-target ΔRFP (HSP90rr+RAD/WT-RAD) with coefficient of determination, R2.
List of induced proteins by functional groups
| Category and gene ID | Annotation | WT+RAD vs WT-RAD | ||
|---|---|---|---|---|
| ΔRFP | ΔRNA | ΔTE | ||
| Protein folding/chaperones | ||||
| LinJ.22.0670 | A2 protein | +2.873 | +0.576 | +2.297 |
| LinJ.33.0940 | DnaJ, putative | +1.169 | −0.241 | +1.410 |
| LinJ.27.2350 | DnaJ, putative | +1.059 | +0.550 | +0.509 |
| LinJ.25.2290 | DnaJ/zinc-finger double-stranded RNA-binding, putative | +1.064 | +0.813 | +0.250 |
| LinJ.29.1360 | HSP100 | +0.674 | +0.301 | +0.373 |
| LinJ.34.0230 | HSP23 | +1.086 | −0.495 | +1.581 |
| LinJ.28.3040 | HSP70, putative | +1.024 | −0.328 | +1.352 |
| LinJ.33.0350 | HSP90 | +1.601 | +0.372 | +1.230 |
| LinJ.30.2480 | mtHSP70 | +1.535 | +0.321 | +1.215 |
| LinJ.04.0710 | Tir chaperone protein (CesT) family | −1.076 | +0.431 | −1.507 |
| LinJ.36.2190 | TPR repeat, putative | +1.027 | +0.607 | +0.420 |
| LinJ.26.0360 | TPR repeat, putative | −1.078 | +0.000 | −1.078 |
| LinJ.05.0410 | TPR repeat, putative | −1.160 | −0.677 | −0.483 |
| Redox enzymes | ||||
| LinJ.32.2880 | As/Sb reductase, putative | +1.256 | −0.919 | +2.175 |
| LinJ.34.0070 | Ascorbate peroxidase, putative | +1.845 | +0.481 | +1.363 |
| LinJ.31.2600 | Ferredoxin, 2Fe-2S-like protein | +0.934 | +0.122 | +0.813 |
| LinJ.27.0670 | Glutaredoxin-like protein | +1.396 | −0.241 | +1.637 |
| LinJ.26.0770 | Glutathione peroxidase-like protein, putative | +2.512 | +0.576 | +1.936 |
| LinJ.26.0780 | Glutathione peroxidase-like protein, putative | +1.274 | +0.582 | +0.692 |
| LinJ.32.1910 | Iron superoxide dismutase, putative | +1.275 | +0.010 | +1.265 |
| LinJ.23.0500 | Trypanothione synthetase, putative | +1.207 | −0.060 | +1.268 |
| LinJ.29.1250 | Tryparedoxin 1 | +1.170 | +0.430 | +0.740 |
| LinJ.15.1140 | Tryparedoxin peroxidase | +1.120 | +0.235 | +0.885 |
| LinJ.15.1100 | Tryparedoxin peroxidase | +1.029 | +0.406 | +0.623 |
| Proteolytic enzymes | ||||
| LinJ.26.2720 | CAAX prenyl protease 2, putative | +1.270 | +0.122 | +1.148 |
| LinJ.14.0920 | Calpain-like cysteine peptidase, putative | +2.157 | +0.247 | +1.910 |
| LinJ.20.1210 | Calpain-like cysteine peptidase, putative | +1.067 | +0.045 | +1.023 |
| LinJ.36.6520 | Carboxypeptidase, putative | +1.700 | +0.177 | +1.523 |
| LinJ.14.0180 | Carboxypeptidase, putative | +1.051 | +0.339 | +0.712 |
| LinJ.22.1540 | Metallopeptidase, clan MA(E), family M3, putative, partial | +1.746 | −0.475 | +2.222 |
| LinJ.36.4230 | Metallopeptidase, clan MC, family M14, putative | +1.022 | +0.268 | +0.754 |
| LinJ.09.1360 | PPPDE putative peptidase domain-containing protein, putative | +1.369 | −0.530 | +1.900 |
| LinJ.34.4390 | Proteasome beta 7 subunit, putative | +2.134 | −0.610 | +2.745 |
| LinJ.01.0730 | Ubiquitin-activating enzyme, putative | +1.050 | −0.129 | +1.179 |
| LinJ.28.0500 | Ubiquitin-activating enzyme, putative | −1.348 | −1.345 | −0.003 |
| LinJ.36.4580 | Ubiquitin protein ligase, putative (fragment) | +1.256 | −0.134 | +1.390 |
| LinJ.32.0730 | Ubiquitin-conjugating enzyme E2, putative | +1.099 | +0.759 | +0.340 |
| LinJ.21.0500 | Ubiquitin-conjugating enzyme-like protein | +1.026 | +0.278 | +0.747 |
| LinJ.31.1930 | Ubiquitin-fusion protein | +2.716 | +0.889 | +1.826 |
| LinJ.13.0620 | Ubiquitin-like protein | +1.185 | +0.145 | +1.040 |
| Amastin family | ||||
| LinJ.30.1490 | Ama1 protein, putative | +1.256 | −0.521 | +1.777 |
| LinJ.08.0650 | Amastin surface glycoprotein, putative | +1.058 | +0.421 | +0.637 |
| LinJ.08.0780 | Amastin-like protein | +2.157 | +1.218 | +0.938 |
| LinJ.08.0680 | Amastin-like protein | +2.104 | +0.122 | +1.983 |
| LinJ.34.1040 | Amastin-like protein | +2.078 | +0.374 | +1.704 |
| LinJ.29.1450 | Amastin-like protein | +1.513 | +0.806 | +0.706 |
| LinJ.08.0760 | Amastin-like protein | +1.034 | +0.759 | +0.275 |
| LinJ.24.1300 | Amastin-like surface protein-like protein | +2.597 | −0.589 | +3.186 |
| LinJ.34.1680 | Amastin-like surface protein, putative | +2.303 | −0.241 | +2.544 |
| LinJ.34.1010 | Amastin-like surface protein, putative | +1.809 | +0.566 | +1.242 |
| LinJ.34.1020 | Amastin-like surface protein, putative | +1.527 | +0.264 | +1.263 |
| LinJ.34.1690 | Amastin-like surface protein, putative | +1.349 | −0.978 | +2.327 |
| LinJ.34.1730 | Amastin-like surface protein, putative | +1.031 | +0.185 | +0.845 |
| LinJ.34.1150 | Amastin-like surface protein, putative | +1.015 | +0.396 | +0.619 |
| LinJ.29.3010 | Amastin, putative | +4.303 | +0.049 | +4.255 |
| LinJ.29.3030 | Amastin, putative | +2.283 | +0.555 | +1.727 |
| LinJ.31.0460 | Amastin, putative | +1.443 | +0.213 | +1.230 |
| LinJ.29.3000 | Amastin, putative | +1.157 | +0.174 | +0.983 |
| Chromatin proteins | ||||
| LinJ.20.0460 | Cell cycle checkpoint protein RAD1-like, putative (fragment) | −1.481 | −0.978 | −0.503 |
| LinJ.28.2550 | DNA replication licensing factor MCM6, putative | −1.098 | −1.148 | +0.050 |
| LinJ.09.0930 | Histone H1-like protein | +1.041 | +0.280 | +0.761 |
| LinJ.09.0930 | Histone H1-like protein | +1.041 | +0.280 | +0.761 |
| LinJ.27.1120 | Histone H1, putative | +1.387 | +0.377 | +1.011 |
| LinJ.27.1070 | Histone H1, putative | +1.040 | +0.096 | +0.944 |
| LinJ.27.1120 | Histone H1, putative | +1.387 | +0.377 | +1.011 |
| LinJ.27.1070 | Histone H1, putative | +1.040 | +0.096 | +0.944 |
| LinJ.29.1850 | Histone H2A, putative | +5.007 | +1.081 | +3.927 |
| LinJ.29.1870 | Histone H2A, putative | +2.050 | −0.759 | +2.809 |
| LinJ.29.1850 | Histone H2A, putative | +5.007 | +1.081 | +3.927 |
| LinJ.29.1870 | Histone H2A, putative | +2.050 | −0.759 | +2.809 |
| LinJ.19.0040 | Histone H2B | +2.688 | −0.796 | +3.484 |
| LinJ.09.1410 | Histone H2B | +1.532 | −0.493 | +2.025 |
| LinJ.19.0040 | Histone H2B | +2.688 | −0.796 | +3.484 |
| LinJ.09.1410 | Histone H2B | +1.532 | −0.493 | +2.025 |
| LinJ.16.0600 | Histone H3, putative | +1.240 | −0.505 | +1.744 |
| LinJ.16.0600 | Histone H3, putative | +1.240 | −0.505 | +1.744 |
| LinJ.36.0020 | Histone H4 | +1.443 | −1.328 | +2.771 |
| LinJ.15.0010 | Histone H4 | +1.034 | −0.210 | +1.245 |
| LinJ.35.0020 | Histone H4, putative, pseudogene | +1.204 | −0.108 | +1.313 |
| LinJ.30.1010 | Histone-binding protein RBBP4, putative | −1.388 | −1.463 | +0.076 |
| LinJ.26.0710 | Regulator of chromosome condensation (RCC1) repeat, putative | +1.671 | −0.189 | +1.860 |
| Protein kinases | ||||
| LinJ.27.1680 | Casein kinase I-like protein | −2.651 | +0.022 | −2.673 |
| LinJ.29.2260 | Cdc2-related kinase 10, putative | +1.231 | +0.039 | +1.191 |
| LinJ.33.1930 | Dual-specificity protein kinase, putative | +1.993 | +0.929 | +1.064 |
| LinJ.35.4060 | Protein kinase A catalytic subunit isoform 1 | +1.335 | +0.185 | +1.149 |
| LinJ.32.1350 | Protein kinase domain-containing protein, putative | +1.619 | +0.039 | +1.580 |
| LinJ.32.1350 | Protein kinase domain-containing protein, putative | +1.619 | +0.039 | +1.580 |
| LinJ.29.0380 | Protein kinase-like protein | +1.267 | +0.921 | +0.346 |
| LinJ.17.0440 | Protein kinase, putative | +2.207 | +0.451 | +1.756 |
| LinJ.35.4690 | Protein kinase, putative | +1.256 | −1.700 | +2.957 |
| LinJ.14.1510 | Protein kinase, putative | +1.050 | +0.633 | +0.416 |
| LinJ.19.0590 | Protein kinase, putative | −1.191 | −0.300 | −0.891 |
| LinJ.19.1510 | Protein kinase, putative | −1.329 | +0.344 | −1.673 |
| LinJ.19.1640 | Protein kinase, putative | −1.651 | −1.241 | −0.410 |
| LinJ.28.3240 | Serine/threonine kinase, putative | +1.157 | −0.978 | +2.135 |
| Fatty acid metabolism | ||||
| LinJ.14.0770 | Fatty acid elongase, putative | +1.934 | −0.826 | +2.760 |
| LinJ.14.0710 | Fatty acid elongase, putative | +1.083 | −0.027 | +1.109 |
| LinJ.14.0720 | Fatty acid elongase, putative | −1.124 | +0.344 | −1.468 |
| LinJ.14.0750 | Fatty acid elongase, putative | −1.236 | −0.241 | −0.995 |
| LinJ.14.0670 | Fatty acid elongase, putative | −1.622 | +0.149 | −1.771 |
| LinJ.01.0520 | Fatty acyl-CoA synthetase 2, putative | −1.918 | −0.794 | −1.124 |
| LinJ.03.0220 | Long-chain fatty acyl-CoA synthetase, putative | −1.482 | −0.241 | −1.241 |
| LinJ.01.0540 | Long-chain-fatty acid-CoA ligase, putative | −1.663 | −0.014 | −1.650 |
Positive numbers indicate log2 increases, while negative numbers indicate log2 decreases.
FIG 5Sequence alignment of HSP90 chaperone family members in L. infantum. MUSCLE alignment of the deduced N-terminal amino acid sequences of 3 HSP90 paralogues, with the conserved Leu residues of HSP90 indicated by an arrow.